Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Vertex provided a revenue guidance range of $11.75 billion to $12 billion for 2025, which would amount to an increase of 6.6% to 8.9%. Management anticipates continued strong performance from its ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

Australian exchange operator ASX said on Thursday it had recorded higher new listings and total quoted capital in the first ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the ... Although Vertex has seen solid sales growth lately, its operating margin has contracted by 1,150 bps from 51.4% in ...